Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Liabilities: 2020-2025

Historic Total Liabilities for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to $53.1 million.

  • Caribou Biosciences' Total Liabilities fell 15.83% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 15.83%. This contributed to the annual value of $60.4 million for FY2024, which is 5.40% down from last year.
  • As of Q3 2025, Caribou Biosciences' Total Liabilities stood at $53.1 million, which was down 2.98% from $54.8 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Total Liabilities high stood at $80.2 million for Q2 2023, and its period low was $35.7 million during Q1 2021.
  • In the last 3 years, Caribou Biosciences' Total Liabilities had a median value of $62.5 million in 2024 and averaged $62.4 million.
  • As far as peak fluctuations go, Caribou Biosciences' Total Liabilities spiked by 1,426.28% in 2021, and later decreased by 22.09% in 2024.
  • Over the past 5 years, Caribou Biosciences' Total Liabilities (Quarterly) stood at $54.5 million in 2021, then soared by 33.67% to $72.9 million in 2022, then dropped by 12.46% to $63.8 million in 2023, then declined by 5.40% to $60.4 million in 2024, then fell by 15.83% to $53.1 million in 2025.
  • Its Total Liabilities was $53.1 million in Q3 2025, compared to $54.8 million in Q2 2025 and $56.4 million in Q1 2025.